Cargando…

Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial

AIMS: Biomarker‐driven prognostic models incorporating N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity cardiac troponin T (hs‐cTnT) in heart failure (HF) with preserved ejection fraction (HFpEF) are lacking. We aimed to generate a biomarker‐driven prognostic tool for patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pocock, Stuart J., Ferreira, João Pedro, Packer, Milton, Zannad, Faiez, Filippatos, Gerasimos, Kondo, Toru, McMurray, John J.V., Solomon, Scott D., Januzzi, James L., Iwata, Tomoko, Salsali, Afshin, Butler, Javed, Anker, Stefan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Focused Issue on Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796853/ https://www.ncbi.nlm.nih.gov/pubmed/35796209 http://dx.doi.org/10.1002/ejhf.2607

Ejemplares similares

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021)

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2021)

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
por: Packer, Milton, et al.
Publicado: (2021)

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2023)

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
por: Zannad, Faiez, et al.
Publicado: (2022)

Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
por: Pocock, Stuart J, et al.
Publicado: (2021)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
por: Anker, Stefan D., et al.
Publicado: (2022)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Lam, Carolyn S P, et al.
Publicado: (2021)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
por: Packer, Milton, et al.
Publicado: (2020)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
por: Zannad, Faiez, et al.
Publicado: (2020)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled
por: Verma, Subodh, et al.
Publicado: (2023)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
por: Anker, Stefan D., et al.
Publicado: (2020)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
por: Packer, Milton, et al.
Publicado: (2023)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fsd513ilbfim04248tlodta43d